IN2015DN00139A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN00139A IN2015DN00139A IN139DEN2015A IN2015DN00139A IN 2015DN00139 A IN2015DN00139 A IN 2015DN00139A IN 139DEN2015 A IN139DEN2015 A IN 139DEN2015A IN 2015DN00139 A IN2015DN00139 A IN 2015DN00139A
- Authority
- IN
- India
- Prior art keywords
- domain
- car
- human
- antigen binding
- methods
- Prior art date
Links
- 230000011664 signaling Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671508P | 2012-07-13 | 2012-07-13 | |
| PCT/US2013/050293 WO2014012001A2 (en) | 2012-07-13 | 2013-07-12 | Use of cart19 to deplete normal b cells to induce tolerance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00139A true IN2015DN00139A (ru) | 2015-06-12 |
Family
ID=49916701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN139DEN2015 IN2015DN00139A (ru) | 2012-07-13 | 2013-07-12 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150290244A1 (ru) |
| EP (1) | EP2872184B1 (ru) |
| JP (4) | JP2015523386A (ru) |
| KR (1) | KR102216083B1 (ru) |
| CN (1) | CN104884095A (ru) |
| AU (3) | AU2013289984B2 (ru) |
| BR (1) | BR112015000657B1 (ru) |
| CA (1) | CA2876734A1 (ru) |
| EA (2) | EA201992742A3 (ru) |
| ES (1) | ES2835232T3 (ru) |
| IN (1) | IN2015DN00139A (ru) |
| MX (2) | MX2015000433A (ru) |
| WO (1) | WO2014012001A2 (ru) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| CN105358576B (zh) | 2013-02-20 | 2020-05-05 | 诺华股份有限公司 | 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症 |
| US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| KR102487608B1 (ko) | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| CN112481283A (zh) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| JP7084138B2 (ja) | 2014-08-19 | 2022-06-14 | ノバルティス アーゲー | 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ） |
| WO2016028879A1 (en) * | 2014-08-19 | 2016-02-25 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating immune response |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| CN114621969A (zh) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞 |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| EP3240803B1 (en) | 2014-12-29 | 2021-11-24 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CN114958764A (zh) | 2015-04-08 | 2022-08-30 | 诺华股份有限公司 | Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法 |
| EP4234685A3 (en) | 2015-04-17 | 2023-09-06 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3903586A1 (en) | 2015-05-06 | 2021-11-03 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| SG10201912978PA (en) | 2015-07-21 | 2020-02-27 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| CN108348620A (zh) * | 2015-09-28 | 2018-07-31 | 明尼苏达大学董事会 | 嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预 |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| AU2017248817A1 (en) * | 2016-04-15 | 2018-11-15 | The Children's Hospital Of Philadelphia | Compositions and methods of chimeric alloantigen receptor T cells |
| PL3443096T3 (pl) * | 2016-04-15 | 2023-06-19 | Novartis Ag | Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| MA45784A (fr) * | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps |
| AR110676A1 (es) | 2016-10-07 | 2019-04-24 | Novartis Ag | Tratamiento del cáncer utilizando receptores de antígenos quiméricos |
| CN110234327A (zh) * | 2016-11-30 | 2019-09-13 | 英特拉克森公司 | 类固醇施用和免疫疗法 |
| EP3346001A1 (en) * | 2017-01-06 | 2018-07-11 | TXCell | Monospecific regulatory t cell population with cytotoxicity for b cells |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| AU2018237159A1 (en) | 2017-03-22 | 2019-09-05 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
| CN112739340A (zh) * | 2018-07-23 | 2021-04-30 | 美真达治疗公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| US20230227583A1 (en) | 2019-08-30 | 2023-07-20 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| TW202134285A (zh) | 2019-11-26 | 2021-09-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| US20230055186A1 (en) * | 2019-12-27 | 2023-02-23 | Zhaotai Immugene Biomedicine (Hong Kong) Limited | Engineered immune killer cell, preparation method therefor and use thereof |
| CN115190803A (zh) * | 2020-01-10 | 2022-10-14 | 共免疫公司 | 治疗肿瘤的方法 |
| WO2022047424A1 (en) | 2020-08-31 | 2022-03-03 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005306585A1 (en) * | 2004-11-17 | 2006-05-26 | Nuon Therapeutics Pty Limited | A method of modulating B cell functioning |
| FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| EP1795588A1 (en) * | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
| CA2754266A1 (en) * | 2009-03-06 | 2010-09-10 | Medimmune, Llc | Humanized anti-cd19 antibody formulations |
| WO2011059836A2 (en) * | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9133436B2 (en) * | 2010-02-04 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | ICOS critically regulates the expansion and function of inflammatory human Th17 cells |
| MX347078B (es) * | 2010-12-09 | 2017-04-10 | Univ Pennsylvania | Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer. |
| JP5897035B2 (ja) * | 2010-12-14 | 2016-03-30 | ユニバーシティ オブ メリーランド，ボルチモア | 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法 |
-
2013
- 2013-07-12 BR BR112015000657-4A patent/BR112015000657B1/pt active IP Right Grant
- 2013-07-12 EA EA201992742A patent/EA201992742A3/ru unknown
- 2013-07-12 EP EP13816739.0A patent/EP2872184B1/en active Active
- 2013-07-12 JP JP2015521846A patent/JP2015523386A/ja not_active Withdrawn
- 2013-07-12 MX MX2015000433A patent/MX2015000433A/es unknown
- 2013-07-12 CA CA2876734A patent/CA2876734A1/en active Pending
- 2013-07-12 AU AU2013289984A patent/AU2013289984B2/en active Active
- 2013-07-12 KR KR1020157002826A patent/KR102216083B1/ko active IP Right Grant
- 2013-07-12 ES ES13816739T patent/ES2835232T3/es active Active
- 2013-07-12 IN IN139DEN2015 patent/IN2015DN00139A/en unknown
- 2013-07-12 WO PCT/US2013/050293 patent/WO2014012001A2/en active Application Filing
- 2013-07-12 EA EA201590209A patent/EA034644B1/ru not_active IP Right Cessation
- 2013-07-12 CN CN201380037500.6A patent/CN104884095A/zh active Pending
- 2013-07-12 US US14/413,100 patent/US20150290244A1/en not_active Abandoned
-
2015
- 2015-01-09 MX MX2018009820A patent/MX2018009820A/es unknown
-
2018
- 2018-04-23 JP JP2018082149A patent/JP2018135363A/ja not_active Withdrawn
- 2018-05-29 AU AU2018203756A patent/AU2018203756B2/en active Active
- 2018-06-04 US US15/996,667 patent/US20180271907A1/en not_active Abandoned
-
2020
- 2020-01-16 AU AU2020200315A patent/AU2020200315B2/en active Active
- 2020-07-01 JP JP2020113687A patent/JP2020158541A/ja not_active Withdrawn
-
2022
- 2022-09-22 JP JP2022150897A patent/JP2022173331A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015000433A (es) | 2016-04-28 |
| MX2018009820A (es) | 2022-08-24 |
| JP2015523386A (ja) | 2015-08-13 |
| AU2020200315A1 (en) | 2020-02-06 |
| EA201590209A1 (ru) | 2015-08-31 |
| AU2018203756B2 (en) | 2019-10-24 |
| WO2014012001A3 (en) | 2015-04-23 |
| EP2872184B1 (en) | 2020-09-16 |
| JP2018135363A (ja) | 2018-08-30 |
| AU2018203756A1 (en) | 2018-06-21 |
| KR102216083B1 (ko) | 2021-02-17 |
| AU2020200315B2 (en) | 2021-11-04 |
| CN104884095A (zh) | 2015-09-02 |
| JP2022173331A (ja) | 2022-11-18 |
| EP2872184A4 (en) | 2016-03-30 |
| KR20150030750A (ko) | 2015-03-20 |
| US20180271907A1 (en) | 2018-09-27 |
| WO2014012001A2 (en) | 2014-01-16 |
| US20150290244A1 (en) | 2015-10-15 |
| EA201992742A3 (ru) | 2020-12-30 |
| EA201992742A2 (ru) | 2020-09-30 |
| EP2872184A2 (en) | 2015-05-20 |
| AU2013289984A1 (en) | 2015-01-22 |
| ES2835232T3 (es) | 2021-06-22 |
| EA034644B1 (ru) | 2020-03-02 |
| CA2876734A1 (en) | 2014-01-16 |
| AU2013289984B2 (en) | 2018-03-08 |
| BR112015000657A8 (pt) | 2018-01-16 |
| BR112015000657B1 (pt) | 2023-12-05 |
| BR112015000657A2 (pt) | 2017-06-27 |
| JP2020158541A (ja) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00139A (ru) | ||
| IN2014DN07414A (ru) | ||
| MX2013006570A (es) | Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer. | |
| IN2014DN11155A (ru) | ||
| IN2014DN06522A (ru) | ||
| MX2018005618A (es) | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. | |
| IL285475A (en) | Antibodies against dendritic cell antigen 2 of blood and uses thereof | |
| MX2014010183A (es) | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. | |
| TN2015000050A1 (en) | Methods of treating a tauopathy | |
| MX2016004420A (es) | Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr. | |
| MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
| TN2013000246A1 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| TN2014000207A1 (en) | Anti il-36r antibodies |